BioHarvest Sciences (BHST) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
7 May, 2026Mission and vision
Focused on addressing unmet health and wellness needs with patentable plant compounds produced sustainably and economically.
Aims to discover, develop, manufacture, and democratize life-changing plant-based compounds for global health and wellness while preserving the planet.
Technology and platform
Invented botanical synthesis, isolating and maximizing phytonutrients by growing only plant cells, not whole plants.
Over $100M invested in a patented platform with 14 granted patents and multiple pending.
Facilities optimized for industrial production, requiring low CapEx and offering high ROI; $5M investment can yield $60M in annual revenue.
Process enables consistent, clean, non-GMO, and highly potent compounds with significant environmental and economic advantages.
Product portfolio and growth engines
Two main growth engines: direct-to-consumer (D2C) packaged products and CDMO services for plant-based compounds.
Flagship product VINIA® has achieved over $84M in sales since 2021, with 85,000+ active customers and strong clinical validation.
Expanding product lines include hydration powders, chews, coffee, tea, and future launches based on olive and pomegranate cell powders.
CDMO division has signed four deals across cosmetics, pharma, nutraceuticals, and sweeteners, with a robust pipeline and multi-billion-dollar market opportunities.
Latest events from BioHarvest Sciences
- Record revenue growth and market leadership achieved through patented botanical synthesis.BHST
Corporate presentation10 Apr 2026 - Revenue up 37% to $34.5M, gross margin 59.3%, strong cash, and robust 2026 outlook.BHST
Q4 202510 Apr 2026 - Q3 revenue up 101% to $6.5M, gross margin 57%, and strong VINIA subscriber and CDMO growth.BHST
Q3 202412 Jan 2026 - Seeks up to $100M for R&D and expansion amid ongoing losses and high operational risks.BHST
Registration Filing16 Dec 2025 - 2024 revenue up 99% to $25.2M, gross margin at 57%, and strong CDMO growth outlook.BHST
Q4 20241 Dec 2025 - 41% revenue growth, 60% gross margin, and new channels drive path to Q4 EBITDA breakeven.BHST
Q2 202523 Nov 2025 - Plant cell biotech drives growth with scalable tech, high-margin CDMO, and expanding product lines.BHST
Canaccord Genuity’s 45th Annual Growth Conference23 Nov 2025 - Q1 revenue up 47% to $7.9M, gross margin 58.5%, net loss narrowed, strong VINIA and CDMO growth.BHST
Q1 202519 Nov 2025 - Q3 revenue up 39% to $9.1M, gross margin at 61%, and $30.8M raised for growth.BHST
Q3 202517 Nov 2025